Study to Assess the Safety, Pharmacokinetics/Dynamics of DS-1040b in Subjects With Acute Submassive Pulmonary Embolism

A phase 1/2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 134 participants.

Also called NCT02923115

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 1/2
Enrolled
  • 134 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02923115
  • EudraCT 2015-005211-32
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Austria, Belgium, France, Germany, Italy, Netherlands, Spain (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02923115. Randomized; double masking; primary purpose treatment. Start 2016-06-23 (actual); primary completion 2019-08-05 (actual). Results posted on 2020-07-30.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study to Assess the Safety, Pharmacokinetics/Dynamics of DS-1040b in Subjects With Acute Submassive Pulmonary Embolism
Condition
Thrombotic Disease
Intervention (Drug)
DS-1040b
Intervention (Drug)
Placebo
Intervention (Drug)
Enoxaparin
Lead sponsor
Daiichi Sankyo (class: industry)

Record details

Record id
cardio:ct-nct02923115
Content hash
3e884e310fd413828df46f40af6802ef0f8cb2d154c7a476083675631548ff21